The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.

Olivia  White

No Relationships to Disclose

Susan Faye  Dent

Honoraria - Novartis

Consulting or Advisory Role - AstraZeneca; BMS US; Novartis; Roche; Roche

Research Funding - Novartis (Inst)

Kelly E.  Westbrook

Honoraria - Gilead Sciences

Research Funding - Novartis; Seagen

Heather  Moore

Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Novartis